Search Results - "Wysham, Carol H."

Diabetes Performance Measures: Current Status and Future Directions by O'CONNOR, Patrick J, BODKIN, Noni L, TAYLOR, Michael L, WYSHAM, Carol H, FRADKIN, Judith, GLASGOW, Russell E, GREENFIELD, Sheldon, GREGG, Edward, KERR, Eve A, PAWLSON, L. Gregory, SELBY, Joseph V, SUTHERLAND, John E

“…[...] as process measures and measures of risk factor control have improved in the U.S., a concomitant reduction in several major adverse outcomes (kidney…”
Get full text

In reply—Long-term Efficacy and Safety of Exenatide Treatment by Wysham, Carol H., MD

Get full text

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data by Young, James B, Gauthier-Loiselle, Marjolaine, Bailey, Robert A, Manceur, Ameur M, Lefebvre, Patrick, Greenberg, Morris, Lafeuille, Marie-Hélène, Duh, Mei Sheng, Bookhart, Brahim, Wysham, Carol H

“…There exist several predictive risk models for cardiovascular disease (CVD), including some developed specifically for patients with type 2 diabetes mellitus…”
Get full text

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study by Wysham, Carol H, Rosenstock, Julio, Vetter, Marion L, Wang, Hui, Hardy, Elise, Iqbal, Nayyar

“…IntroductionInvestigate the effects of switching from two times per day exenatide to once-weekly exenatide administered by autoinjector (exenatide once-weekly…”
Get full text

New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals by Wysham, Carol H.

“…Diabetes mellitus is a complex and increasingly common metabolic disease that is characterized by hyperglycemia and associated with microvascular and…”
Get full text

Five-Year Efficacy and Safety Data of Exenatide Once Weekly by Wysham, Carol H., MD, MacConell, Leigh A., PhD, Maggs, David G., MD, Zhou, Ming, PhD, Griffin, Peter S., BA, Trautmann, Michael E., MD

“…Abstract Objective To evaluate the 5-year efficacy and safety of once weekly exenatide. Patients and Methods The Diabetes Therapy Utilization: Researching…”
Get full text

GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date by Brunton, Stephen A., Wysham, Carol H.

“…Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system responsible for a variety of glucoregulatory effects, including glucose-dependent secretion…”
Get full text

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors by Wysham, Carol H, Lefebvre, Patrick, Pilon, Dominic, Ingham, Mike, Lafeuille, Marie-Hélène, Emond, Bruno, Kamstra, Rhiannon, Chow, Wing, Pfeifer, Michael, Duh, Mei Sheng

“…Achieving control of glycated hemoglobin (HbA1c), blood pressure (BP), and body weight (BW) remains a challenge for most patients with type 2 diabetes mellitus…”
Get full text

Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial by Wysham, Carol H, MacConell, Leigh, Hardy, Elise

“…This study investigated the efficacy and safety of multiple exenatide once-monthly suspension (QMS) doses of exenatide-containing microspheres in Miglyol…”
Get full text

743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials by WYSHAM, CAROL H., TOFE, SANTIAGO, SAPIN, HELENE, MALIK, RALEIGH, NEFF, LISA M.

“…Tirzepatide (TZP) is a dual GIP and GLP-1 receptor agonist developed for the treatment of patients with type 2 diabetes (T2D) . The SURPASS clinical trials…”
Get full text

Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis by Wysham, Carol H., Lin, Jay, Kuritzky, Louis

“…Objective: To consolidate the evidence from randomized controlled trials evaluating the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as add-on…”
Get full text

Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study by Philis-Tsimikas, Athena, Wysham, Carol H., Hardy, Elise, Han, Jenny, Iqbal, Nayyar

“…To investigate the glycemic efficacy, effects on cardiovascular risk factors, and safety of exenatide once weekly (QW) in patients with type 2 diabetes over…”
Get full text

100-OR: ADA Presidents’ Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1) by ROSENSTOCK, JULIO, WYSHAM, CAROL H., FRIAS, JUAN P., KANEKO, SHIZUKA, LEE, CLARE, LANDO, LAURA FERNANDEZ, MAO, HUZHANG, CUI, XUEWEI, THIEU, VIVIAN

“…Tirzepatide (TZP) is a novel dual GIP/GLP-1 receptor agonist in development for type 2 diabetes (T2D). Efficacy and safety of TZP vs. placebo (PBO) was…”
Get full text

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications by Wysham, Carol H, Campos, Carlos, Kruger, Davida

“…Novel co-formulations of basal insulin analogs and glucagon-like peptide-1 (GLP-1) receptor agonists have provided new options for patients with type 2…”
Get full text

Target Fasting Plasma Glucose (FPG) without Nocturnal Hypoglycemia in Patients with Type 1 Diabetes or Type 2 Diabetes—Results from SWITCH Trials by Wysham, Carol H, Lane, Wendy, Ladelund, Steen, Tutkunkardas, Deniz, Heller, Simon

“…Insulin degludec (degludec) is a basal insulin that results in a lower FPG than insulin glargine 100 units/mL (glargine U100), which may increase the risk of…”
Get full text

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes by Wysham, Carol H., Rosenstock, Julio, Vetter, Marion L., Dong, Fang, Öhman, Peter, Iqbal, Nayyar

“…Aims To simplify administration of aqueous exenatide once weekly, which requires reconstitution, the exenatide microspheres have been reformulated in a…”
Get full text

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial by Wysham, Carol H, MacConell, Leigh A, Maggs, David G, Zhou, Ming, Griffin, Peter S, Trautmann, Michael E

“…To evaluate the 5-year efficacy and safety of once weekly exenatide. The Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors…”
Get full text

Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes by Miller, Eden M, Wysham, Carol H

Get full text

Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals by LaRue, Susan, Springer, Jane, Noderer, Michael, Meehan, James, Wysham, Carol H.

“…Background: Ease of injection is important to patients. An autoinjector was developed to deliver exenatide, a glucagon-like peptide-1 receptor agonist for type…”
Get full text

Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study by Wysham, Carol H., Gauthier-Loiselle, Marjolaine, Bailey, Robert A., Manceur, Ameur M., Lefebvre, Patrick, Greenberg, Morris, Duh, Mei Sheng, Young, James B.

“…Objective: To develop and validate models allowing the prediction of major adverse chronic renal outcomes (MACRO) in patients with type 2 diabetes mellitus…”
Get full text